 Antihypertensive Agents
"Antihypertensive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
| Descriptor ID |
D000959
|
| MeSH Number(s) |
D27.505.954.411.162
|
| Concept/Terms |
Antihypertensive Agents- Antihypertensive Agents
- Agents, Antihypertensive
- Antihypertensives
- Anti-Hypertensives
- Anti Hypertensives
- Antihypertensive Drugs
- Drugs, Antihypertensive
- Anti-Hypertensive Agents
- Agents, Anti-Hypertensive
- Anti Hypertensive Agents
- Anti-Hypertensive Drugs
- Anti Hypertensive Drugs
- Drugs, Anti-Hypertensive
|
Below are MeSH descriptors whose meaning is more general than "Antihypertensive Agents".
Below are MeSH descriptors whose meaning is more specific than "Antihypertensive Agents".
This graph shows the total number of publications written about "Antihypertensive Agents" by people in UAMS Profiles by year, and whether "Antihypertensive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 2 | 1 | 3 | | 2020 | 4 | 4 | 8 | | 2019 | 1 | 2 | 3 | | 2018 | 3 | 4 | 7 | | 2017 | 2 | 1 | 3 | | 2016 | 3 | 1 | 4 | | 2015 | 0 | 2 | 2 | | 2014 | 10 | 2 | 12 | | 2013 | 7 | 4 | 11 | | 2012 | 9 | 3 | 12 | | 2011 | 2 | 3 | 5 | | 2010 | 3 | 4 | 7 | | 2009 | 3 | 1 | 4 | | 2008 | 1 | 4 | 5 | | 2007 | 0 | 2 | 2 | | 2006 | 3 | 3 | 6 | | 2005 | 1 | 0 | 1 | | 2004 | 2 | 3 | 5 | | 2003 | 2 | 0 | 2 | | 2002 | 4 | 1 | 5 | | 2001 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1997 | 4 | 0 | 4 | | 1996 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antihypertensive Agents" by people in Profiles over the past ten years.
-
Jafar TH, Tan NC, Shirore RM, Allen JC, Finkelstein EA, Hwang SW, Koong AYL, Moey PKS, Kang GC, Goh CWT, Subramanian RC, Thiagarajah AG, Ramakrishnan C, Lim CW, Liu J. Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore-A cluster randomized controlled trial. PLoS Med. 2022 06; 19(6):e1004026.
-
Dalli LL, Andrew NE, Kim J, Cadilhac DA, Sanfilippo FM, Thrift AG, Nelson MR, Lannin NA, Olaiya MT, Ryan OF, Booth B, Gall S, Kilkenny MF. Understanding of medications and associations with adherence, unmet needs, and perceived control of risk factors at two years post-stroke. Res Social Adm Pharm. 2022 09; 18(9):3542-3549.
-
Adeneye AA, Olorundare OE, Omobowale TO, Akinsola AO, Kolo PM, Albrecht RMA, Crooks PA. Selected Antihypertensive Agents and Their Fixed-Dose Combinations Effectively Ameliorate Trastuzumab-Mediated Cardiac Dysfunction In Rats. Niger J Physiol Sci. 2021 Jun 30; 36(1):57-65.
-
Mohandas R, Chamarthi G, Bozorgmehri S, Carlson J, Ozrazgat-Baslanti T, Ruchi R, Shukla A, Kazory A, Bihorac A, Canales M, Segal MS. Pro Re Nata Antihypertensive Medications and Adverse Outcomes in Hospitalized Patients: A Propensity-Matched Cohort Study. Hypertension. 2021 08; 78(2):516-524.
-
Allen JC, Halaand B, Shirore RM, Jafar TH. Statistical analysis plan for management of hypertension and multiple risk factors to enhance cardiovascular health in Singapore: the SingHypertension pragmatic cluster randomized controlled trial. Trials. 2021 Jan 19; 22(1):66.
-
Mathur P, Kadavath S, Marsh JD, Mehta JL. Chronotherapy for hypertension: improvement in patient outcomes with bedtime administration of antihypertensive drugs. Eur Heart J. 2020 12 21; 41(48):4577-4579.
-
Henry D. Antihypertensive drugs and COVID-19. Heart. 2021 01; 107(1):85.
-
Sharma T, Mathur P, Mehta JL. Daytime or Nighttime Administration of Antihypertensive Medications? Am J Hypertens. 2020 11 03; 33(11):987-989.
-
Gawrys O, Husková Z, Baranowska I, Walkowska A, Sadowski J, Kikerlová S, Vanourková Z, Honetschlägerová Z, Škaroupková P, Cervenka L, Falck JR, Imig JD, Kompanowska-Jezierska E. Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. J Hypertens. 2020 09; 38(9):1802-1810.
-
Teeter BS, Thomas JL, Curran GM, Balamurugan A. Classifying intervention modifications in the community pharmacy context: A demonstration study. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):e230-e235.
-
Critser PJ, Higano NS, Lang SM, Kingma PS, Fleck RJ, Hirsch R, Taylor MD, Woods JC. Cardiovascular magnetic resonance imaging derived septal curvature in neonates with bronchopulmonary dysplasia associated pulmonary hypertension. J Cardiovasc Magn Reson. 2020 07 23; 22(1):50.
-
Magvanjav O, Cooper-Dehoff RM, McDonough CW, Gong Y, Hogan WR, Johnson JA. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. Am J Hypertens. 2020 04 01; 33(4):316-324.
-
Modrall JG, Zhu H, Weaver FA. Clinical predictors of blood pressure response after renal artery stenting. J Vasc Surg. 2020 10; 72(4):1269-1275.
-
Raisingani M, Brar PC. Characterization of the duration of treatment with diazoxide in infants with prolonged hyperinsulinism (PHI). J Pediatr Endocrinol Metab. 2019 Nov 26; 32(11):1241-1245.
-
Amr BS, Lippmann M, Tobbia P, Isom N, Dalia T, Buechler T, Pierpoline M, Patel N, Hockstad E, Wiley M, Tadros P, Mehta A, Earnest M, Chen JG, Gupta K. Impact of short term oral steroid use for intravenous contrast media hypersensitivity prophylaxis in diabetic patients undergoing nonemergent coronary angiography or interventions. Catheter Cardiovasc Interv. 2020 12; 96(7):1392-1398.
-
Inger HE, McGregor ML, Jordan CO, Reem RE, Aylward SC, Scoville NM, Bai S, Rogers DL. Surgical intervention in pediatric intracranial hypertension: incidence, risk factors, and visual outcomes. J AAPOS. 2019 04; 23(2):96.e1-96.e7.
-
Magvanjav O, Cooper-DeHoff RM, McDonough CW, Gong Y, Segal MS, Hogan WR, Johnson JA. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. J Clin Hypertens (Greenwich). 2019 01; 21(1):91-101.
-
Sedláková L, Kikerlová S, Husková Z, Cervenková L, Chábová VC, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Krátký V, Cervenka L, Kopkan L. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep. 2018 10 31; 38(5).
-
Ahmed HA, Ishrat T, Pillai B, Fouda AY, Sayed MA, Eldahshan W, Waller JL, Ergul A, Fagan SC. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018 Aug 13; 15(1):229.
-
Correa A, Rochlani Y, Khan MH, Aronow WS. Pharmacological management of hypertension in the elderly and frail populations. Expert Rev Clin Pharmacol. 2018 Aug; 11(8):805-817.
-
Cervenka L, Husková Z, Kopkan L, Kikerlová S, Sedláková L, Vanourková Z, Alánová P, Kolár F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neckár J. Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. J Hypertens. 2018 06; 36(6):1326-1341.
-
Pakravan M, Esfandiari H, Yazdani S, Doozandeh A, Dastborhan Z, Gerami E, Kheiri B, Pakravan P, Yaseri M, Hassanpour K. Clinical outcomes of Ahmed glaucoma valve implantation in pediatric glaucoma. Eur J Ophthalmol. 2019 Jan; 29(1):44-51.
-
Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, Breitenstein S, Chen C, Diacovo T, Feltes T, Furlong P, Hanna M, Graham EM, Hsu D, Ivy DD, Murphy D, Kammerman LA, Kearns G, Lawrence J, Lebeaut B, Li D, Male C, McCrindle B, Mugnier P, Newburger JW, Pearson GD, Peiris V, Percival L, Pina M, Portman R, Shaddy R, Stockbridge NL, Temple R, Hill KD. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. J Am Heart Assoc. 2018 02 10; 7(4).
-
Rochlani Y, Khan MH, Aronow WS. Managing Hypertension in Patients Aged 75 Years and Older. Curr Hypertens Rep. 2017 Oct 18; 19(11):88.
-
Hogan WR, Hanna J, Hicks A, Amirova S, Bramblett B, Diller M, Enderez R, Modzelewski T, Vasconcelos M, Delcher C. Therapeutic indications and other use-case-driven updates in the drug ontology: anti-malarials, anti-hypertensives, opioid analgesics, and a large term request. J Biomed Semantics. 2017 Mar 03; 8(1):10.
-
Rochlani Y, Khan MH, Banach M, Aronow WS. Are two drugs better than one? A review of combination therapies for hypertension. Expert Opin Pharmacother. 2017 Mar; 18(4):377-386.
-
Theodoropoulou S, Ellabban AA, Johnston RL, Cilliers H, Mohamed Q, Sallam AB. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2017 Apr; 255(4):725-732.
-
Bagherani N, Smoller BR. Efficacy of bimatoprost in the treatment of non-facial vitiligo. Dermatol Ther. 2017 Mar; 30(2).
-
Khurshid K, Yabes J, Weiss PM, Dharia S, Brown L, Unruh M, Jhamb M. Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. J Clin Sleep Med. 2016 08 15; 12(8):1143-51.
-
Jafar TH, Tan NC, Allen JC, Pradhan SS, Goh P, Tavajoh S, Keng FM, Chan J. Management of hypertension and multiple risk factors to enhance cardiovascular health - a feasibility study in Singapore polyclinics. BMC Health Serv Res. 2016 07 08; 16:229.
-
Hye Khan MA, Sharma A, Rarick KR, Roman RJ, Harder DR, Imig JD. Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats. PLoS One. 2015; 10(12):e0145335.
-
Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension. 2015 Mar; 65(3):476-82.
-
Diaz KM, Veerabhadrappa P, Brown MD, Whited MC, Dubbert PM, Hickson DA. Prevalence, Determinants, and Clinical Significance of Masked Hypertension in a Population-Based Sample of African Americans: The Jackson Heart Study. Am J Hypertens. 2015 Jul; 28(7):900-8.
-
Sporková A, Jíchová S, Husková Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
-
Pakravan M, Yazdani S. Author reply: To PMID 24819857. Ophthalmology. 2014 Dec; 121(12):e69.
-
Bano M, Kanaan UB, Ehrlich AC, McCracken C, Morrow G, Oster ME, Sachdeva R. Improvement in Tricuspid Annular Plane Systolic Excursion with Pulmonary Hypertension Therapy in Pediatric Patients. Echocardiography. 2015 Aug; 32(8):1228-32.
-
Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ, Fendley H, Probstfield JL, Whelton PK, Davis BR. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014 Nov; 29(11):1475-83.
-
Pettey CM, McSweeney JC, Stewart KE, Price ET, Cleves MA, Heo S, Souder E. Perceptions of family history and genetic testing and feasibility of pedigree development among African Americans with hypertension. Eur J Cardiovasc Nurs. 2015 Feb; 14(1):8-15.
-
Hye Khan MA, Pavlov TS, Christain SV, Neckár J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond). 2014 Oct; 127(7):463-74.
-
Hye Khan MA, Neckár J, Cummens B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther. 2014 Aug; 28(4):313-22.
-
Padilla Ramos A, Varon J. Current and newer agents for hypertensive emergencies. Curr Hypertens Rep. 2014 Jul; 16(7):450.
-
Rajan S, Deogaonkar M, Kaw R, Nada EM, Hernandez AV, Ebrahim Z, Avitsian R. Factors predicting incremental administration of antihypertensive boluses during deep brain stimulator placement for Parkinson's disease. J Clin Neurosci. 2014 Oct; 21(10):1790-5.
-
Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, Santoro EP, McCrary Sisk C, Blaustein RO. A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol. 2014 Aug 07; 9(8):1441-8.
-
Pakravan M, Rad SS, Yazdani S, Ghahari E, Yaseri M. Effect of early treatment with aqueous suppressants on Ahmed glaucoma valve implantation outcomes. Ophthalmology. 2014 09; 121(9):1693-8.
-
Lampert BC, Eckert C, Weaver S, Scanlon A, Lockard K, Allen C, Kunz N, Bermudez C, Bhama JK, Shullo MA, Kormos RL, Dew MA, Teuteberg JJ. Blood pressure control in continuous flow left ventricular assist devices: efficacy and impact on adverse events. Ann Thorac Surg. 2014 Jan; 97(1):139-46.
-
Anderson A, Walker BR. 11ß-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs. 2013 Sep; 73(13):1385-93.
-
Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97.
-
Wiggs JL, Hauser MA, Abdrabou W, Allingham RR, Budenz DL, Delbono E, Friedman DS, Kang JH, Gaasterland D, Gaasterland T, Lee RK, Lichter PR, Loomis S, Liu Y, McCarty C, Medeiros FA, Moroi SE, Olson LM, Realini A, Richards JE, Rozsa FW, Schuman JS, Singh K, Stein JD, Vollrath D, Weinreb RN, Wollstein G, Yaspan BL, Yoneyama S, Zack D, Zhang K, Pericak-Vance M, Pasquale LR, Haines JL. The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variables. J Glaucoma. 2013 Sep; 22(7):517-25.
-
Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr. 2013 Jun; 25(3):329-37.
-
Nahas R, Pain T, Goulden P. A rare cause of epigastric pain in a middle-aged man. BMJ Case Rep. 2013 Apr 25; 2013.
-
Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin Exp Pharmacol Physiol. 2013 Apr; 40(4):273-81.
-
Juncos L. Direct renin inhibition: extricating facts from façades. Ther Adv Cardiovasc Dis. 2013 Jun; 7(3):153-67.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|